Roivant Sciences Ltd (ROIV) concluded trading on Thursday at a closing price of $10.62, with 3.48 million shares of worth about $36.91 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 6.20% during that period and on August 01, 2024 the price saw a loss of about -2.12%. Currently the company’s common shares owned by public are about 806.68M shares, out of which, 481.86M shares are available for trading.
Stock saw a price change of -1.12% in past 5 days and over the past one month there was a price change of 0.57%. Year-to-date (YTD), ROIV shares are showing a performance of -5.43% which decreased to -10.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.24 but also hit the highest price of $13.24 during that period. The average intraday trading volume for Roivant Sciences Ltd shares is 4.84 million. The stock is currently trading -3.29% below its 20-day simple moving average (SMA20), while that difference is down -2.15% for SMA50 and it goes to 0.68% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Roivant Sciences Ltd (NASDAQ: ROIV) currently have 806.68M outstanding shares and institutions hold larger chunk of about 60.19% of that.
The stock has a current market capitalization of $7.85B and its 3Y-monthly beta is at 1.24. PE ratio of stock for trailing 12 months is 2.10, while it has posted earnings per share of $5.07 in the same period. It has Quick Ratio of 25.10 while making debt-to-equity ratio of 0.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ROIV, volatility over the week remained 2.94% while standing at 2.62% over the month.
Stock’s fiscal year EPS is expected to drop by -119.86% while it is estimated to decrease by -8.00% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on February 15, 2024 offering an Outperform rating for the stock and assigned a target price of $17 to it. Coverage by Piper Sandler stated Roivant Sciences Ltd (ROIV) stock as an Overweight in their note to investors on January 05, 2024, suggesting a price target of $20 for the stock. On December 12, 2023, Deutsche Bank Initiated their recommendations, while on October 17, 2023, Guggenheim Initiated their ratings for the stock with a price target of $17. Stock get a Neutral rating from BofA Securities on June 08, 2023.
